Page last updated: 2024-11-13

(S)-warfarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## (S)-Warfarin: A Powerful Tool for Research

**(S)-warfarin** is the **enantiomer** of the drug **warfarin**, which is a common anticoagulant used to prevent blood clots. It's important to understand that **warfarin is a racemic mixture**, meaning it's composed of two enantiomers (mirror images): (S)-warfarin and (R)-warfarin.

**Why is (S)-warfarin important for research?**

* **Stronger Anticoagulant Activity:** (S)-warfarin is significantly **more potent** as an anticoagulant compared to (R)-warfarin. This makes it a valuable tool for studying the mechanism of action of warfarin and developing new anticoagulants.
* **Understanding Enantiomer Specificity:** Researching (S)-warfarin helps scientists understand the **role of chirality** (the spatial arrangement of atoms) in drug activity. This is crucial for drug development, as enantiomers can often have different pharmacological effects.
* **Investigating Warfarin's Diverse Applications:** Warfarin has applications beyond blood clotting prevention, such as cancer research. (S)-warfarin is used to investigate these applications and its potential in treating various conditions.
* **Developing New Drug Delivery Systems:** The specific properties of (S)-warfarin can aid in the development of new drug delivery systems, such as **nanoparticles** for targeted drug delivery.

**Key Research Areas:**

* **Mechanism of Action:** Studying how (S)-warfarin interacts with its target, vitamin K epoxide reductase (VKORC1), to inhibit blood clotting.
* **Pharmacokinetics and Pharmacodynamics:** Analyzing how the body absorbs, distributes, metabolizes, and eliminates (S)-warfarin, and how it affects the coagulation cascade.
* **Development of Warfarin Analogs:** Designing new anticoagulants based on the structure of (S)-warfarin with improved efficacy, safety, and reduced side effects.
* **Therapeutic Applications:** Investigating the potential of (S)-warfarin in treating various diseases, such as cancer and inflammatory disorders.

**In conclusion, (S)-warfarin is a vital research tool for understanding the mechanism of action of anticoagulants, investigating the role of chirality in drug activity, and developing new therapeutic strategies.**

(S)-warfarin : A 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one that has (S)-configuration (the racemate is warfarin, an anticoagulant drug and rodenticide). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54688261
CHEMBL ID251074
CHEBI ID87738
SCHEMBL ID662875
SCHEMBL ID20806

Synonyms (46)

Synonym
BIDD:PXR0197
(s)-(-)-warfarin, >=97% (hplc)
SWF ,
s-warfarin
BIM-0061758.0001
4-hydroxy-3-[(1s)-3-oxo-1-phenylbutyl]-2h-chromen-2-one
NCGC00165934-01
DB02507
1HA2
chebi:87738 ,
CHEMBL251074
A840201
2-hydroxy-3-[(1s)-3-oxo-1-phenyl-butyl]chromen-4-one
C20129
2-hydroxy-3-(3-oxo-1-phenyl-butyl)chromen-4-one
A830639
5543-57-7
2h-1-benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, (s)-
(s)-warfarin
warfarin, (s)-
einecs 226-907-3
(s)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone
unii-hp31w7fnp4
hp31w7fnp4 ,
(-)-warfarin
4-hydroxy-3-[(1s)-3-oxo-1-phenylbutyl]chromen-2-one
BRD-K25991148-001-01-7
PJVWKTKQMONHTI-HNNXBMFYSA-N
SCHEMBL662875
SCHEMBL20806
s(-)-warfarin
(s)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2h-chromen-2-one
levrowarfarin
4-hydroxy-3-[(1s)-3-oxo-1-phenylbutyl]-2h-1-benzopyran-2-one
warfarin, l-
coumarin, 3-(.alpha.-acetonylbenzyl)-4-hydroxy-, (s)-(-)-
4-hydroxy-3-((1s)-3-oxo-1-phenylbutyl)-2h-1-benzopyran-2-one
2h-1-benzopyran-2-one, 4-hydroxy-3-((1s)-3-oxo-1-phenylbutyl)-
(s)-(-)-warfarin
AKOS027320629
2-hydroxy-3-[(1s)-3-oxo-1-phenylbutyl]-4h-chromen-4-one
GS-6170
DTXSID50873382
DB14055
Q27093493
AKOS037653253

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-oneA member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency5.01195.623417.292931.6228AID485281
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, SERUM ALBUMINHomo sapiens (human)Kd2.90002.90002.90002.9000AID977611
Chain A, SERUM ALBUMINHomo sapiens (human)Kd2.90002.90002.90002.9000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID1133000Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 4'-hydroxywarfarin metabolite formation measured for 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1223477Total clearance in iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1132983Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 4-hydroxy-3-(3-oxo-1-phenyl-1-butenyl)-2H-1-benzopyran-2-one metabolite formation at 3 umol measured under acidic conditions by LC-UV analysis in presence of NADPH1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1211795Dissociation constant, pKa of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1132997Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 6-hydroxywarfarin metabolite formation by LC-UV analysis in presence of carbon monoxide-oxygen mixture at ratio of 80:201978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1211791Fraction unbound in human hepatocytes2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1211798Intrinsic clearance in human using well stirred liver model by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1132999Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 4-hydroxy-3-(3-oxo-1-phenyl-1-butenyl)-2H-1-benzopyran-2-one metabolite formation measured for 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1132989Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 4-oxo-3-(3-oxo-1-phenylbut-1-enyl)-4H-chromen-2-olate metabolite formation at 3 umol measured under basic conditions by LC-UV analysis in presence of NADPH1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1133004Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 4'-hydroxywarfarin metabolite formation measured after 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1223487Total clearance in chimeric mouse with humanized liver at 0.3 mg/kg, iv by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1133019Drug metabolism in PCN-induced rat liver microsomes assessed as cytochrome P450-mediated 4-hydroxy-3-(3-oxo-1-phenyl-1-butenyl)-2H-1-benzopyran-2-one metabolite formation at 0.15 mmol measured per nmol of CYP450 under acidic conditions by LC-UV analysis i1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1223486Intrinsic clearance in human hepatocytes from chimeric mouse with humanized liver assessed per 10'6 cells at 10 uM after 0.25 to 2 hrs by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1223482Ratio of drug level in blood to plasma in iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1223483Unbound fraction in iv dosed human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1132984Drug metabolism in phenobarbital-induced rat liver microsomes assessed as cytochrome P450-mediated 4-hydroxy-3-(3-oxo-1-phenyl-1-butenyl)-2H-1-benzopyran-2-one metabolite formation at 3 umol measured under acidic conditions by LC-UV analysis in presence o1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1133006Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 7-hydroxywarfarin metabolite formation measured after 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1211793Lipophilicity, log P of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1211792Hepatic clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1132998Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 7-hydroxywarfarin metabolite formation by LC-UV analysis in presence of carbon monoxide-oxygen mixture at ratio of 80:201978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1211794Fraction unbound in blood (not specified)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1223481Elimination half life iv dosed human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1132990Drug metabolism in phenobarbital-induced rat liver microsomes assessed as cytochrome P450-mediated 4-oxo-3-(3-oxo-1-phenylbut-1-enyl)-4H-chromen-2-olate metabolite formation at 3 umol measured under basic conditions by LC-UV analysis in presence of NADPH1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1132995Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 4-hydroxy-3-(3-oxo-1-phenyl-1-butenyl)-2H-1-benzopyran-2-one metabolite formation by LC-UV analysis in presence of carbon monoxide-oxygen mixture at ratio of 80:201978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1211797Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1132996Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 4'-hydroxywarfarin metabolite formation by LC-UV analysis in presence of carbon monoxide-oxygen mixture at ratio of 80:201978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1133003Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 4-hydroxy-3-(3-oxo-1-phenyl-1-butenyl)-2H-1-benzopyran-2-one metabolite formation measured after 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1133001Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 6-hydroxywarfarin metabolite formation measured for 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1133005Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 6-hydroxywarfarin metabolite formation measured after 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1132994Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 4-hydroxy-3-(3-oxo-1-phenyl-1-butenyl)-2H-1-benzopyran-2-one metabolite formation by LC-UV analysis in presence of nitrogen1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1133002Drug metabolism in rat liver microsomes assessed as cytochrome P450-mediated 7-hydroxywarfarin metabolite formation measured for 10 mins by LC-UV analysis1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
A new warfarin metabolite: structure and function.
AID1223474Elimination half life in chimeric mouse with humanized liver at 0.3 mg/kg, iv by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1811Experimentally measured binding affinity data derived from PDB2001The Journal of biological chemistry, Jun-22, Volume: 276, Issue:25
Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2001The Journal of biological chemistry, Jun-22, Volume: 276, Issue:25
Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]